---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070387"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:43:41.702283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HeartSciences Q2 cash $100K, equity deficit; raises $9.3M post-quarter, Mount Sinai deal expands AI-ECG platform

## Summary
- Q2 FY2024: no significant revenue; cash ~$100K; shareholders' equity deficit ~$1.6M as of Oct 31, 2023.
- After quarter close: raised $9.3M net from stock sales, converted $1.1M debt to equity, closed license agreements with Mount Sinai (became material shareholder).
- FDA confirmed 510(k) pathway for MyoVista wav ECG device; target clearance in CY2024, expected to save millions and years for future algorithms.
- Expanded IP to 42 patents; new distributor agreements in India and Nordic countries; selected by CardiACT for Irish police officer screening.
- CEO states shareholders' equity now >$5M; may seek second 180-day Nasdaq bid price grace period if needed.

## SEC filing metadata
- accession: 0000950170-23-070387
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/0000950170-23-070387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/hscs-20231214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070387
- JSON: https://secwatch.observer/filing/0000950170-23-070387.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070387.txt

## Key facts
- Earnings Releases
  HeartSciences Inc. reported the second quarter fiscal 2024 ended October 31, 2023 results: revenue There were no significant revenues.
  - Period: the second quarter fiscal 2024 ended October 31, 2023
  - Revenue: There were no significant revenues
  - Result: reported results
  source text: Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/0000950170-23-070387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.